AC Immune SA (ACIU) Gets a Buy Rating from H.C. Wainwright

By Ryan Adsit

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on AC Immune SA (ACIUResearch Report) today and set a price target of $11.00. The company’s shares closed last Monday at $8.67.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 11.5% and a 47.2% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Cyclacel Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AC Immune SA with a $11.00 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $12.50 and a one-year low of $3.25. Currently, AC Immune SA has an average volume of 102.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.